New data spotlight menin inhibitors as a targeted therapeutic strategy for KMT2A‑rearranged acute leukemias, a genetically defined and aggressive subtype. Researchers and early‑stage developers reported activity in preclinical models and early human studies that supports continued clinical development in pediatric and young‑adult populations. Menin inhibitors disrupt the menin‑MLL interaction that sustains oncogenic transcription in KMT2A fusions. Investigators described mechanistic validation, dose‑response relationships, and combination strategies to prevent resistance; sponsors are moving several programs into expanded trials to define safety and durable response rates.